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Abstract
Two classes of drugs, antiretrovirals and antibiotics, could benefit greatly from delivery
through microneedles. Microneedles (MN) offer an increase in efficacy for these drugs by
providing delivery to the lymphatic system through the skin, thus avoiding first pass metabolism
and allowing more focused delivery to specific viral or bacterial reservoirs. Furthermore,
microneedles present other advantages in the form of the ability to be self-administered, tunable
controlled release, and painless administration. Saquinavir and Ciprofloxacin, an antiretroviral
and an antibiotic respectively, were chosen for their optimal properties, including bioavailability,
half-life, and dosage. Saquinavir was encapsulated in the organic phase of biodegradable
poly(lactide-co-glycolide) microparticles (MP) synthesized through a double emulsion.
Similarly, Ciprofloxacin was encapsulated in the aqueous phase of the microparticles. In
addition, Ciprofloxacin microcrystals were synthesized. The microparticles and microcrystals
were then loaded into molded polymer microneedles in a poly-acrylic acid (PAA) matrix.
Standard curves were created for the two drugs from known concentrations and used to show the
drug loading in the microparticles and microneedles. The Saquinavir microparticles showed a
maximum loading of 1.35% the mass of particles and the Ciprofloxacin microparticles showed a
maximum loading of 0.197%. The Saquinavir microparticle microneedles had a maximum
loading of 11.95 sg of Saquinavir per 1 cm2 array and the Ciprofloxacin microparticle
microneedles had a maximum loading of .41 pg of Ciprofloxacin per 1 cm2 array. The
Ciprofloxacin microcrystal microneedlees had a maximum loading of 165 pg per 1 cm2 array.
Analysis based on insulin delivery through microneedles showed these loadings to be too low to
create the sufficient minimum drug concentration in plasma. However, there exist multiple
strategies to increase the loading of the drugs in the microneedles. These results proved
promising for the use of microneedles for the delivery of antiretroviral and antibiotic drugs.
Thesis Supervisor: Darrell J. Irvine
Title: Associate Professor of MSE and Biological Engineering
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I Introduction
a. Background
Drug delivery has become an increasingly important field with continued advances in
drug discovery. Just as important as how the drug acts is how it is delivered. Historically, drugs
have been delivered into the human body through two main forms: orally through pills and
directly into the bloodstream through hypodermic injections'. Controlled release transdermal
drug delivery offers numerous benefits over the aforementioned forms of drug delivery. Drug
patches and microneedles (MN) are two methods for transdermal delivery that have been
thoroughly investigated2 3 . The drug patches are limited to only a handful of drugs, while
microneedles have the capability to be much more universal in the drugs they can introduce'.
Orally delivered drugs must traverse the digestive system, which to can lead to a loss of
drug as it is absorbed across the intestinal wall as well as losses due to the first pass effect from
the liver metabolizing the drug 2. The drug must also be able to remain intact after being exposed
to the harsh environment of the digestive system, including acidity of the stomach and numerous
enzymes throughout the intestines'. The drug's charge and solubility affect the absorption the
drug's absorption and create an extra parameter in designing the drug. Finally, the drug can
cause side effects to the digestive system and is susceptible to a varied digestive environment
dependent on other foods in the digestive system2.
Hypodermic injections, including intravenous (IV), intramuscular, subcutaneous, and
intradermal injections, eliminate many of these problems because they bypass the digestive
system and the drug is delivered directly into the bloodstream. These injections, however, are
more invasive and have a number of undesired characteristics 4. Improper maintenance and use
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of needles can also lead to infections4 . The needles used for injections can become dangerous
medical waste and pose the danger of transmitting diseases through shared needle use, which is
prevalent in developing and poverty stricken nations 12 . Administering these injections usually
requires special training and expertise (e.g. finding a vein for IV injection or using correct angle
for subcutaneous injections).
Transdermal delivery is a further improvement on injections; it bypasses the digestive
system, but doesn't have the drawbacks or pose the dangers that other types of injections do.
Transdermal delivery was first developed as a patch loaded with the drug that would diffuse
across the stratum corneum into the skin over time1 . The most well known example is the
Nicoderm CQ patch, which introduces nicotine into the patient at gradually smaller amounts to
help the user quit smoking. However, due to the low permeability of the skin, only small drug
molecules (molecular masses of up to a few hundred Daltons) with specific octanol-water
partition coefficients can be used to deliver therapeutic doses with patches" 2 . These limitations
rule out many hydrophilic drugs, as well as macromolecules, such as DNA and peptide drugs.
Thus microneedles are an advantageous form of transdermal delivery since they can be used for
a larger variety of drugs and more efficiently transmit the drug; instead of relying on diffusion
for the drug to pass the outer skin layer, microneedles physically place the drug into the body. A
huge benefit of delivering drugs transderrnally is the ability to access the epidermal and top of
the dermal layer of the skin. This means that the microneedles are short enough to avoid the
nerve endings and therefore not cause pain, while also accessing certain immune cells that are
critical to the drug efficacy5. Langerhans cells, which are present in the epidermal layer, are
susceptible to human immunodeficiency virus (HIV) infection and are known to be viral
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reservoirs of dissemination. By directly targeting these viral reservoirs, anti-HIV therapies
could be more effective.
Figure 1 below gives the envisioned application of delivery of the drug using the
microneedles. The solid PAA matrix of the polyacrylic acid (PAA) microneedles encapsulate
either drug crystals or drugs suspended in poly(lactide-co-glycolide) (PLGA) microparticles.
The microneedles are inserted into the epidermal or dermal layers of the skin to release the drug.
The PAA matrix dissolves when it comes in contact with the water based skin fluids, releasing
either the drug crystals or the drug microparticles. The drug crystals become soluble in the skin
fluid due to low concentrations and potentially due to a change in pH and the PLGA matrix of
the drug microparticles similarly dissolves in the water based skin fluid, releasing the drug. The
drug is then able to diffuse to key areas of interest.
(a)
T (b) (c) (d) (e)
50-200 um Epidermis
1500-3000 um Dermis
Hypodermis
Figure 1: Envisioned application and delivery of drug through microneedles. (a) Microneedles
are synthesized with polyacrylic acid (PAA) base with either microparticles or microcrystals
suspended in matrix of PAA (b) microneedles are inserted into the skin and access the top layer
of the dermis or bottom of epidermis depending on size of microneedles and application strength
(c) PAA matrix begins to dissolve due to hydrolysis from water in body (d) most of matrix is
dissolved and microparticles release drug or microcrystals dissolve due to pH (e) Complete
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dissolution of microneedle and microparticles or microcrystals leaving dissolved drug to diffuse
away to areas of interest, including lymphatic cells such as Langerhans cells
b. Scope of work
This paper investigates the use of microneedles as a plausible mechanism for drug
delivery. Two classes of drugs are examined because of the potential increase of efficacy with
these drugs by using microneedles. Antiretroviral and antibiotic drugs are hypothesized to
greatly benefit from delivery using microneedles due to the access of particular immune cells in
the epidermal layer as well as bypassing first pass metabolism, in addition to painless, self-
administered delivery.
This work builds upon previous work that has investigated microneedle use for vaccine
delivery. Therefore, certain protocols have already been established and certain parameters
optimized. There still exist a variety of parameters to optimize, including the form of the drug
loaded into the microneedle. This affects the amount of drug that can be loaded into a single
microneedle array as well as delivery rates of the drug. Microparticles, where the drug was
embedded in a matrix of PLGA, and microcyrstals, pure crystalline drug, were both investigated
as possible methods for drug encapsulation. Microparticles would have more controllable drug
release rates, while microcrystals allow for higher loading levels. Other encapsulation methods,
such as using reservoirs and coating the microneedle surfaces, also exist that can be investigated
in future studies.
An outline of the work achieved is shown in Figure 2, below. Two candidate drugs,
Maraviroc and Saquinavir, were used to demonstrate the ability to encapsulate antiretroviral
drugs in microneedles while Ciprofloxacin was used to demonstrate the ability to similarly
encapsulate antiobiotic drugs. A standard curve was created for each drug, followed by synthesis
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of drug microparticles and drug microcrystals. The microparticles were then tested for loading
and both the microparticles and microcrystals were encapsulated in microneedles. These
microneedles were then tested for loading to demonstrate the ability to encapsulate drugs in
microneedles.
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ANTIRETROVIRALS
Saquinavir
SMPs
IL K g
L g
Maraviroc
ANTIBIOTICS
Ciprofloxacin
MPs .
I
I1LVg
Figure 2: Outline of work accomplished. Shown are microparticles (MPs), microcrystals (MCs)
and microneedles (MN)
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II Microneedle Delivery of Antiretroviral Drugs
a. Introduction
In 2009, HIV infected an estimated 36 million people worldwide, with the vast
majority of those infected living in developing nations with limited access to treatment
resources9. Current antiretroviral (AR) therapies have proven to be highly effective in
controlling HIV replication and consequently increase the life expectancy of patients. These
therapies, however, require frequent and high doses and have a number of undesirable side
effects, all of which lead to patient incompliance. In addition, in order to be effective,
compliance above 95% is needed, below which, the AR effectiveness can drop as much as
50%'0'". AR therapies also do not fully eliminate the virus from the host and are unable to
remove viral reservoirs. Therefore, a drug delivery method that decreases dose amount and
frequency and improves patient incompliance as well as targets viral reservoirs would be a
drastic improvement over current methods. Microneedles are able to access these viral reservoirs
and would decrease the dosage required since they deliver drugs directly into the epidermal layer
of the skin and completely bypass the digestive tract. In addition, they can be tuned for desired
controlled release rates, allowing for a sustained critical effective level of drug, a major benefit
over the large variations in drug concentrations with pills.
A number of factors were used in determining candidate drugs. Drugs which could
benefit maximally from microneedle delivery would have low half-lives, high potency, low
bioavailibilities, and require frequent doses. Microneedles would have the most improvement in
efficacy with drugs with these characteristics because microneedles are able to replace frequent
doses with controlled release strategies and are able to effectively deliver drugs, overcoming low
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bioavailability. High potency is desirable because of the limitation of microneedles for
delivering large amounts of drug due to their size. For the 650 pm height and 250 pm width
microneedles we fabricated, this results in 1 IL per microneedle, which is approximately .012
mg of Saquinavir with a density of 1.2 g/cm 3 assuming 100% loading of pure Saquinavir12 . The
microneedle arrays have 78 microneedles, indicating a maximum of 0.94 mg of Saquinavir per
array.
Microparticles allow for tunable controlled release of the drug. They are essentially
encapsulating the drug in a biodegradable matrix with a known hydrolysis rate. Once the
microparticles enter the body, they would mostly remain localized due to their size and release
the drug to be taken up into systemic circulation. At low levels, the microparticles might be
carried to the draining lymph nodes by antigen presenting cells, releasing the drug directly to the
lymph nodes.
b. Materials and methods
i. Drug Choice
Table 1 below shows the two drugs chosen as candidate drugs based on the desired
characteristics. Bioavailability is defined as the amount of drug that reaches the systemic
circulation. Terminal half life is the amount of time to reduce plasma concentrations by half
while elimination half life is the amount of time it takes for the drug to lose half of its
pharmacological activity.
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Saquinavir .4% to 5% 3 Terminal: 2-5 17 1000-1200 " 100 '
10-12 14
Elimination:
1-3 15,16
Maraviroc 23% 21 Terminal: 2 20 1200 20 25 24
14-18 2
Elimination:
10.6 23
Table 1: Drug properties for Saquinavir and Maraviroc used to select candidate drugs
Saquinavir is a potent protease inhibitor that is available in two forms, as a soft-gel
capsule with trade name Fortovase, and in the form of a salt, Saquinavir-mesylate, with the trade
name Invirase. The latter, Saquinavir-mesylate, was obtained from Sigma-Aldrich, with
structure shown below in Figure 3.
H
N
0
CH 3
N-f-CH, 0
CHI . H3C SO
0
Figure 3: The structure of Saquinavir in the mesylate form, obtained from Sigma Aldrich 28
Maraviroc is a potent antiretroviral entry inhibitor, acting as a CCR5 chemokinereceptor
antagonist. It is sold with the trade name Selzentry and was also obtained from Sigma-Aldrich.
Its structure is shown below in Figure 4.
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NJ '' M F
H3C F
NNNJ
H3C CH3
Figure 4: The structure of Maraviroc, obtained from Sigma Aldrich 30
ii. Standard curves
In order to determine concentrations of drugs, standard curves were created for both
Maraviroc and Saquinavir. Using a Thermo-Scientific Multiskan GO ultraviolet-visible (UV)
spectrophotometer, samples of known concentration were created and the intensity of the peak
absorption of these concentrations was used to create a standard curve.
1. Saquinavir
Saquinavir has a low aqueous solubility of 2.22 mg/mL and was dissolved in dimethyl-
sulfoxide (DMSO) at 5 mg/mL, the solubility in DMSO according to Sigma 27,28. To control for
the fact that sodium hydroxide (NaOH) would be used to hydrolyze the microparticles and
microneedles, the dilutions were made in 0.2 M NaOH. In addition, due to the UV absorbance
of the polystyrene disposable cuvettes, a Starna Cells quartz open top 10 mm cuvette was used to
eliminate any false signals from the polystyrene cuvettes. The UV spectrophotometer was set to
quick read from 200 nm to 450 nm.
2. Maraviroc
16
Maraviroc also has a low aqueous solubility and was initially dissolved at 30 mg/mL, the
solubility according to Sigma 30. Similarly, the dilutions were made in 0.2 M NaOH to control
for the NaOH that would be used to hydrolyze the microparticles and microneedles. The quartz
cuvette was used in favor of the disposable polystyrene cuvette as soon as it was discovered that
the polystyrene cuvettes were giving false signals and had strong absorption in the UV range,
particularly at the wavelengths of interest. The UV spectrophotometer was set to quick read
from 200 nm to 450 nm.
iii. Microparticle synthesis
The microparticle synthesis is a double emulsion synthesis that requires multiple steps in
order to encapsulate drug in particles of micron diameter. Figure 5 below, outlines these various
steps.
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(a) Internal aqueous phase
(b) Organic phase:
I
(c) External aqueous phase
Figure 5: Microparticle synthesis outline. (a) The internal aqueous phase, drug could be loaded
here, is sonicated as it is added to an organic phase (b) The internal aqueous phase therefore
forms nanoparticles in the organic phase, which could also be loaded with drug (c) The organic
phase with nanoparticles of the internal aqueous phase is then added to an external aqueous
phase as the external aqueous phase is homogenized. (c) The organic phase-internal aqueous
phase then forms microparticles in the external aqueous phase
For reasons discussed below in results and discussion, only Saquinavir was continued as
a candidate drug due to impracticality of measuring concentrations of Maraviroc. However, a
control was also created with the exact same synthesis, but without the addition of the
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Saquinavir. Saquinavir was encapsulated into microparticles that would act as the controlled
release mechanism. The microparticle synthesis was a double emulsion synthesis where an
internal aqueous phase was suspended in an organic phase, which was then suspended in a
second external aqueous phase. Figure 6 shows the structure of the microparticles.
Internal aqueous phase
External aqueous phase
Organic phase
Figure 6: Microparticles with drug loaded in the organic phase
The double emulsion allows flexibility for drugs of different polarity to be loaded into the
microparticle. Due to the low solubility of Saquinavir in aqueous solutions, Saquinavir was
loaded into the organic phase. Although the additional step of the addition of the internal
aqueous phase is unnecessary, it was kept to demonstrate the flexibility of the double emulsion
synthesis as well as to be consistent with the microparticle syntheses for the aqueous soluble
drugs. Three different syntheses were performed, each with a different concentration of
Saquinavir in the organic phase.
1. Organic phase preparation
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Briefly, 50 mg of Saquinavir was dissolved in 1.5625 mL of DMSO for a concentration
of 32 mg/mL. Next 80 mg of poly(lactic acid-co-glycolic acid) (PLGA) from Lakeshore
Biomaterials 50:50 DLG 4A (inherent viscosity 0.35-0.45 dL/g) was dissolved in 5 mL of a mix
of dichloromethane (DCM) and the DMSO+Saquinavir solution in a 10 mL glass vial. Three
different loadings, defined as the ratio of Saquinavir to PLGA were used to examine the effects
of different loadings. A 20% loading solution was made by adding the 80 mg of PLGA to 0.5
mL of DMSO+Saquinavir and 4.5 mL of DCM. A 10% loading solution was made by adding
the 80 mg of PLGA to 0.25 mL of DMSO+Saquinavir and 4.75 mL of DCM. Finally, a 1%
loading solution was made by adding the 80 mg of PLGA to 25 pL of DMSO+Saquinavir to
4.975 mL of DCM. Each solution was shaken for at least 30 minutes to ensure complete
dissolution of PLGA in solution.
2. Aqueous phase preparations
The internal aqueous phase used was simply PBS. The external aqueous phase used was
a 0.5wt% poly(vinyl alcohol) (PVA) solution from MPBiomedicals catalog #151937, with a
molecular weight of 15000. 40 mL of PVA was prepared in a 50 mL Erlenmeyer flask.
3. Particle preparation and work-up
These steps to the particle preparation are outlined above in Figure 5 above. Synthesis
was performed in a fume hood due to the volatile organic solvents. A MISONIX ultrasonic
liquid processor XL-2000 Series sonicator was set to 7 Watts and cleaned alternating with DCM
and acetone for 30 seconds in a 20 mL glass vial, ending with DCM and drying with a Kimwipe.
The same was done for an IKA T25 Digital Ultra-Turrax homogenizer, which was set at 16,000
RPM. The organic phase, which was approximately 5 mL of solution in a 10 mL glass vial, was
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placed in an ice bath and sonicated for 30 seconds with 500 pL of the internal aqueous phase,
PBS, introduced with a micropipette immediately with the beginning of the sonication by
dripping down the sonicator probe tip. While sonicating, the sonicator tip was moved up and
down a number of times and left close to the bottom of the tip to fully emulsify the two solutions.
After 30 seconds, the sonicator was turned off and 10 mL glass vial of the emulsified internal
aqueous phase and organic phase was replaced with the Erlenmeyer flask containing the 40 mL
of external aqueous phase. The homogenizer was placed into the external aqueous flask on ice
and the first emulsion was added by glass pipette again down the homogenizer, but as far into the
solution as possible. The homogenization step lasted 3 minutes, including the approximately 30
seconds to introduce the first emulsion into the second emulsion. After the homogenization, the
flask was stirred overnight in the fume hood to evaporate to remove excess solvent. The first
emulsion created nanoparticles of the internal aqueous phase in the organic phase. The second
emulsion created microparticles of the first emulsion in the external aqueous phase.
After one day, the particle suspensions were then aliquotted into 15 mL conical tubes and
centrifuged at 3000 RPM for 10 minutes. The supernatant was removed and the suspensions
were washed once: -13 mL of Milli-Q (MQ) water was added to each tube, the tubes were
vortexed, centrifuged, and the supernatant was again removed. The suspensions were then
resuspended in 1 mL of MQ water. 200 mL of the suspension was aliquotted into Eppendorf
tubes, usually around 5 to 6 tubes, with the excess kept for particle characterization. These
suspensions were lyophilized to store them. The aliquots were flash frozen in liquid nitrogen and
then perforations were made in the top of the tube before they were placed in vacuum. After a
few days, the lyophilized particle suspensions were then stored in 50 mL conical tubes with
DRIER dessicant and placed in the 4 degree Celsius refrigerator.
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4. Particle Characterization
The particles were then characterized to determine size, zeta potential, concentration, and
yield. To determine concentration and yield, the total excess suspension after storing 200 mL
aliquots was measured to determine the total volume of particle suspension. PCR Eppendorf
tubes were weighed and then aliquots of 25 pL were put in each tube and lyophilized in the same
lyophilization process to store the suspensions. After a few days, these Eppendorf tubes were
weighed and the difference was used to calculate the concentration of the particle suspension.
The microparticle size and zeta potential were determined using a BIC 90+ Particle Analyzer, a
dynamic light scattering (DLS). Polystyrene disposable cuvettes were used and filled to the 10
mm mark with MQ water. 30 pL of the particle suspension was then added. The software was
used to select "uniform spheres" and "liquid" as the type of particles to detect and the base
liquid, respectively. The particle analyzer was run and determined the particle size and
polydispersity. The zeta potential, which is a surface charge measurement that can indicate
stability of colloidal dispersions, was determined in a similar manner. The same diluted solution
of microparticles was pipetted into the rinsed cuvette and the rinsed electrode was placed into the
cuvette with solution. Sufficient solution was added so that the solution covered both electrode
plates. The software was used to enter the size of the particles from the previous step, as well as
set the base liquid to water and the pH to 5.00.
iv. Microparticle loading
To determine the amount of drug that was successful loaded into the microparticles, a
lyophilized aliquot of microparticles with known mass was hydrolyzed for one day with 0.2 M
NaOH. The control microparticles were also hydrolyzed under the same conditions as the
Saquinavir microparticles and were used as the base reading. This was to eliminate any
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interference from signal from PLGA. The solutions were then diluted into the range of the linear
portion of the standard curve and the absorption was determined from the UV visible
spectrophotometer. The linear regression from the standard curve was then used to calculate the
loading.
v. Microneedle synthesis and characterization
The microneedle synthesis from beginning to end is a multi-step process that
requires the use of a number of intermediate processes to create the final drug loaded
microneedle arrays. Figure 7 below outlines the entire process.
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MN Synthesis from PDMS Mold
\/II/1111111/\/\/\/\/(a)
(b)
(e)
(f)
(g)
(h)
(c)
(d) MAAAA '
Figure 7: Outline of the microneedle fabrication process. (a) Master molds were generated from
solid PDMS blocks through laser ablation micro machining of the surface to create the mold
cavities (b) The master molds (c) These master molds were then used to cast PLLA MN arrays
(d) These PLLA MN arrays were used to cure PDMS replicate molds (e) The PDMS replicate
molds were used to create the drug loaded MN arrays (f) The drug, in the form of microcrystals
or microparticles, was deposited onto the molds and centrifuged into the cavities (g) The solution
dried leaving just the microcrystals or microparticles (h) PAA was then deposited and
centrifuged and allowed to dry to create a solid matrix (i) The microneedles were then removed
from the mold and ready to use.
24
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PDMS Mold Fabrication
1. PDMS microneedle mold fabrication
With the particles synthesized, microneedles were then synthesized using
polydimethylsiloxane (PDMS) molds, shown in Figure 8 below. The PDMS mold fabrication
refers to steps (a-e) in Figure 7 above. These PDMS molds were synthesized from poly-L-
lactide (PLLA) microneedles, which were created from master PLLA microneedles that were
created from PDMS master molds, created from laser ablation. The microneedles were mounted
in silicon isolators on the bottom of a culture dish and PDMS precursor and curing agent in a
10:1 ratio (3.8mg curing agent + 34.2 mg PDMS precursor) was mixed well and added. It was
cured at 65C for five hours and then the MNs were removed from the PDMS mold, which was
then sonicated in a jar filled with acetone for 60 minutes. The mold was finally incubated in a
vacuum oven overnight at 140C and finally placed in the freezer for 30 minutes before being
ready to be used.
25
Figure 8: PDMS mold used to synthesize microneedles
2. Microparticle deposition
Both the control microparticles and Saquinavir microparticles were encapsulated in the
microneedles in essentially the same process. Only the highest concentration of the
microparticles was used to maximize the potential loading in the microneedles. 140 gL of MQ
water was deposited into each array well of the PDMS mold and the mold was placed in a
vacuum chamber. The microparticle deposition refers to steps (f-g) of Figure 7 above. Vacuum
was applied carefully a few times for 5-10 seconds in order to remove air bubbles. The addition
of this water is to remove air and allow for the deposition of the particles into the cavities. 70 pL
of the water was removed from each well and replaced with 70 pL of microparticle suspension
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with a concentration of .0285 mg/pL. Both the control "empty" microparticles and the 20%
loaded microparticles aliquots had extremely similar masses of approximately 10.94 mg. This
corresponded to dissolving each aliquot in 383 pL of water and adding 70 pL of solution to each
array well. The molds were centrifuged at 1850 RPM for 15 minutes. The supernatant was
removed and the molds were left to dry on the bench top for an hour.
3. Polyacrylic acid addition
This final step refers to steps (h-i) in Figure 7 above. Following the deposition of the
microparticles, PAA at 35% concentration by weight was added to help the microneedles
maintain their shape and help drive the delivery of the particles. To add the PAA, 2 mm
adhesive silicon isolators were placed on top of the mold and approximately 300 pL of PAA was
added to each well to the brim of the adhesive silicon isolator. The molds were then centrifuged
at 1850 RPM for 25 minutes. The molds were then left to dry on the bench for 48 hours before
they were placed in the dessicator for an additional 48 hours. The microneedles were removed
by placing the molds in the -20C freezer for 30 minutes and using tweezers to pull them out.
They were then stored in the dessicator until use.
4. Microneedle characterization
Microneedles were imaged using an optimal microscope to check dimensions of the
microneedles as well as viewing the separation of particles and PAA. A Leitz DMRX
opticalmicroscope with a Nikon DXM1200F Digital Camera was used.
vi. Microneedle loading
At first, each microneedle array was placed in an Eppendorf tube and 1.5 mL of 0.2 M
NaOH was added so that the microneedle array was fully submerged. After one day, the entire
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microneedle array had hydrolyzed. This method, however, proved impossible due to the
absorbance of PAA.
Instead, each microneedle array was vortexed in 1.5 mL of MQ water for 60 seconds so
only the contents of the tips would be released from the microneedles. The Eppendorf tube was
then centrifuged and the supematant was removed. The contents of the tips were then
hydrolyzed in 0.5mL of 0.2 M NaOH and after a day, the absorbance of the solution was
detected using the UV visible spectrophotometer. The intensity corresponded to the loading
concentration from the standard curve.
c. Results and discussion
i. Standard curves
Saquinavir had a peak absorption at 238 nm and showed a linear optical absorption at this
wavelength over a concentration range from 2.5 pg/mL to 10 pg/mL, as shown in Figure 9,
below. This corresponded to the upper range of the literature value, which was linear from 2.5
ng/mL to 25 ug/mL 26. The standard curve was tested on three different occasions, all plotted
below. The variation from the third could be due to a variety of factors, including contamination
from the cuvette.
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Figure 9: Saquinavir Standard Curve for with error bars from 3 series of measurements
In addition, the 238 nm peak absorption matched reported absorption values from
literature, as is apparent in Figure 10 below.
20
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Figure 10: From Ha et al, the UV-spectrum of Saquinavir-mesylate dissolved in .01M HCl 5
The peak for the Maraviroc dilutions was at 257 nm and was linear and detectable from
concentration 0.3125 mg/mL to 0.1 mg/mL. Figure 11, below, shows the calculated standard
curve from these readings. There was a large difference, however, between this data and
literature data. The literature values for the peaks of absorption were 197 nm and 300 nm and
linear up to 2500 ng/mL. There could be a number of explanations for this discrepancy,
including the limitations of the spectrophotometer to only measure down to 200 nm, but more
likely because the structure has a degree of conjugation that is lower than the threshold needed to
detect a signal with the spectrophotometer. Because of this discrepancy, it was decided not to
continue with Maraviroc because of the uncertainty in determining Maraviroc concentration and
therefore loading of microparticles and microneedles that were loaded with Maraviroc.
Maraviroc Standard Curve
0.45
0.4
E 0.35C
P~f 0.3 - _ _ _ _ _ _ _ _
0.25
y= 0.357x + 0.015
- -R 2 =0.9980.15
C 0.1
0.05
0
0 0.2 0.4 0.6 0.8 1
Concentration (mg/mL)
Figure 11: Maraviroc standard curve at 257 nm zeroed with .2M NaOH + varying levels of
DMSO to match the concentration present in Maraviroc samples. Error bars derived from
replicate measurement zeroed only in 0.2M NaOH.
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ii. Microparticles
The drug-loaded PLGA microparticles were characterized to understand their properties
and hypothesize about how they will act for their intended use and to understand the double
emulsion synthesis. The size, polydispersity, and zeta potential all give insight into how the
particles might dissolve and interact within the body and the yield of the particles indicates how
effective the double emulsion synthesis is in yielding particles. Table 2 shows the results from
the Saquinavir microparticles and the results from the control particles. Both groups of
microparticles had expected properties with no anomalies.
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Yield: Mass of
recovere particles
Microparticles Hydrody PDI d mass per 200uL
namic (polydi Zeta of lyophilize
Diamete spersit potential particles d aliquot
r (nm) S.E. y) S.E. (mV)9 S.E. (%O) (mg9)
PLGA +
Saquinavir
(20%)
(0.5% PVA) 1134.7 29.2 0.061 0.038 -38.51 0.15 75.17% 10.93
PLGA +
Saquinavir
(10%)
(0.5% PVA) 1112.2 84.7 0.073 0.042 -38.21 0.09 93.50% 13.60
PLGA +
Saquinavir
(5%)
(0.5% PVA) 1027.2 20.1 0.064 0.039 -38.08 0.12 77.00% 11.20
Yield:
M prtl recovere Mass per
icropatiles Hydrody PDI d mass 200uL
namic (polydi Zeta of lyophilize
Diamete spersit potential particles d aliquot
r (nm) S.E. y) S.E. (m) S.E. (%) (mg)
PLGA +
DMSO, DCM
(20%)
(0.5% PVA) 1205.8 91.3 0.005 0.000 -42.64 1.55 75.17% 10.93
PLGA +
Dmso, DCM
(10%)
(0.5% PVA) 1727.1 122.3 0.038 0.033 -28.67 1.43 78.83% 11.47
PLGA +
Dmso, DCM
(1%)
(0.5% PVA) 2229.3 157.9 0.141 0.067 -35.23 2.33 64.17% 9.33
Table 2: Characterization results for Saquinavir loaded particles, above, and the control particles,
below.
iii. Microparticle loading
The hydrolyzed microparticles showed higher concentrations of Saquinavir with an
increase in the Saquinavir loading. Table 3 below shows a regression between the loading of the
particles and the actual ratio as determined by the absorbance signal and Figure 12 shows the
correlation graphically with a linear fit.
Actual loading (mass
Loading of Saquinavir per
(Saquinavir:PLGA) mass ofparticles)
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10% 0.98% 1
1% 0.42%
Table 3: The correlation between loading ratio during synthesis and actual loading of
microparticles.
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Figure 12: Correlation shown graphically and approximated as linear between increase in loading
during synthesis and actual loading. No error analysis available due to absence of replication
measurements.
iv. Microneedles
Below, in Figure 13, are images that were taken of the microneedles. The tips are a
different color than the rest of the microneedle due to the microparticles. The rest of the
microneedle is PAA.
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Figure 13: On the left, the Saquinavir microparticle loaded microneedles and on the right, a
higher magnification image of a control microparticle loaded microneedle.
v. Microneedle loading
The absorbance of the microneedle contents hydrolyzed with 0.2 M NaOH overnight,
with a zero base line of the microneedle contents of the microneedles synthesized with the
control particles, showed a strong peak at 240 nm and a small peak at 219 nm, which most likely
correspond to the difference in PLGA between the Saquinavir particles and the control particles.
The microneedles with the 20% loaded Saquinavir showed a loading consistent with
expected results. The 0.899 intensity corresponds to a concentration of .0239 mg/mL. The
microneedle contents were dissolved in 0.5 mL of 0.2 M NaOH, which would correspond to
.0120 mg of Saquinavir per array. With a 20% Saquinavir microparticle loading of 1.35%
determined from the microparticle loading experiment, this would correspond to 883 sg of
particles per microneedle array. Based on the volume of approximately 1 mg per array
calculated previously, this would match the prediction.
Other studies have examined how drugs introduced with microneedles were able to reach
systemic circulation. One such study showed the plasma free insulin levels, after a microneedle
34
injection of 15 units of insulin (approximate total of 682.5 pg of insulin), reached a peak of over
100 microU/mL (4.55 ng/mL)31. For 12 pg of Saquinavir per array, this would translate to 0.08
ng/mL, well below the minimum effective concentration of 100 ng/mL required for Saquinavir.
Because of this factor of 1250, an idea to use drug crystals to maximize the loading of an array
close to the 1 mg limit came about. The use of drug crystals, combined with the using multiple
arrays, could increase the amount of drug delivered to the necessary levels. Further, the
absorption kinetics of Saquinavir could be quite different than that of insulin. In addition,
Saquinavir, unlike insulin, is most effective in the lymphatic system and might have higher
concentration levels in the local lymphatic system.
d. Conclusion
It has been shown that the antiretroviral drug, Saquinavir, can be loaded effectively into
microparticles and that these microparticles can then be loaded in microneedles. It remains
unclear whether the loading is sufficient to completely replace current delivery for Saquinavir,
however these preliminary results are promising. Microneedle deliveries could supplement
current delivery in order to specifically target viral reservoirs.
35
III. Microneedle Delivery of Antibiotics
a. Introduction
Antibiotics are of particular interest due to the prevalence of bacterial infections and because
of the potential for increase in efficacy of these drugs from the delivery of the antibiotics directly
to the lymphatic system. Antibiotics are currently delivered in three main forms: orally and
topically for the majority of infections that are usually localized and intravenously for more
serious, usually systemic infections. One specific application for the microneedle delivery of
antibiotics would be in battlefield situations, where open wounds and battlefield trauma lead to
high risk of infection. The lack of sterile conditions on the battlefield and the delay in being able
to evacuate the casualty both contribute to the need of effective antibiotics. The casualty is
usually treated intravenously with an antibiotic in order to immediately treat the infection.
Microneedle application could be as efficacious, while eliminating the need for trained medical
personnel to set up the IV as well as enabling the casualty to self-apply the antibiotic
immediately. Typical IV dosages are actually similar to the oral pill dosages; IV dosages are
only approximately 20% less35 . Therefore, the use of microneedle delivery of antibiotics to
replace IV introduction of drug would carry the same benefits of replacing high oral pill dosage
and frequent dosage.
This specific application was kept in mind when a candidate drug was selected to test the
feasibility of this idea. In addition, as with the antiretroviral drugs, bioavailability, half-life, and
total dosage were all factors in the drug choice.
b. Materials and Methods
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i. Drug Choice
The drug chosen was Ciprofloxacin based on its desired characteristics, shown below in
Table 4. In addition, Ciprofloxacin is a commonly administered drug on the battlefield for a
variety of injuries12 . Ciprofloxacin, which has the structure shown below in Figure 14, was
obtained from Sigma Aldrich. It is a second generation fluoroqiunolone that targets the
bacteria's ability to rewind its DNA during DNA synthesis.
Drug name Bioavailability Percent Half-life Dose Total Minimum
reach (hours) frequency Daily inhibitory
Circulation (doses/day) Dosage concentration
(mg)
Ciprofloxacin 70%, .5 to 5% ~10% 17 4 23 80032 <1Ipg/mL,
37,38 
.062-
32gg/mL33 ,34
Table 4: Drug properties for Ciprofloxacin that were used to select it as a candidate drug
0 0
F OH
N N
HN I
Figure 14: The structure of Ciprofloxacin, obtained from Sigma Aldrich.3 6
ii. Standard curves
As with Saquinavir, standard curves were created in order to determine the concentration
of Ciprofloxacin in solution. Samples were created with known concentration, diluted, and then
the absorbance was measured with a UV-visible spectrophotometer. The measurements were
recorded to create a standard curve.
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Ciprofloxacin is soluble up to 30 mg/mL in pH 3 solution3 8 . Three different
concentrations were initially made of 30 mg/mL, 10 mg/mL and 5 mg/mL. The corresponding
amount of ciprofloxacin was put in 20 mL of water and then drops of 2.4 N hydrochloric acid
(HCl) were added until the Ciprofloxacin dissolved in solution. The amount of 2.4 N HCl added
was inconsequential compared to the volume of the initial solution. The same glass cuvette used
for the Saquinavir and Maraviroc curve was used for the readings with the UV
spectrophotometer, which did a quick read from 200 nm to 450 nm. The 5 mg/mL solution was
used to initially create the standard curve and was then tested with dilutions from the other two
solutions. In addition, dilutions in 0.2M NaOH were also created at 17 pg/mL and 5 pg/mL to
ensure similar absorbance values since loadings were going to be read in 0.2 M NaOH.
iii. Microparticle synthesis
The microparticle synthesis to encapsulate the ciprofloxacin was the same double
emulsion synthesis as for the Saquinavir; however, the drug ciprofloxacin was encapsulated in
the internal aqueous phase as opposed to the organic phase. Figure 15 below shows the structure
of the microparticle.
Internal aqueous phase
Drug Dru
External aqueous phase
DDrug
Drugg
Organic phase
Figure 15: Microparticles with drug loaded in the internal aqueous phase
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Three syntheses were done for three different concentrations of Ciprofloxacin, 30
mg/mL, 10 mg/mL, and 5 mg/mL.
1. Organic phase preparation
For each synthesis, 80 mg of poly(lactic-co-glycolic) acid (PLGA) from Lakeshore
Biomaterials 5050 DLG 4A (inherent viscosity 0.35-0.45 dL/g) was dissolved in 5 mL of
dichloromethane (DCM). Each solution was shaken for at least 30 minutes for complete
dissolution of PLGA.
2. Aqueous phase preparations
The internal aqueous phase was simply the 30 mg/mL, 10 mg/mL, and 5 mg/mL
solutions of Ciprofloxacin dissolved in water and 2.4 N hydrocholoric acid to create a solution of
approximately pH 2. The external aqueous phase used was 40 mL of .5% poly(vinyl alcohol)
(PVA) solution from MPBiomedicals catalog #151937 with a molecular weight of 15000 that
was prepared in a 50 mL Erlenmeyer flask.
3. Particle preparation and work-up
Particle preparation and work-up was carried out as described in Chapter II, Section
b.iii.3., but with 500 pL of the internal aqueous phase being solutions of ciprofloxacin and the 5
mL of the organic phase being PLGA in DCM.
4. Particle characterization
Particle characterization was carried out as described in Chapter II, Section b.iii.4.
iv. Microparticle loading
Microparticle loading was carried out as described in Chapter II, Section b.iv.
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v. Microcrystals
In addition to the testing of microneedle loading of microparticles, the test of microneedle
loading of microcrystal was also of interest. Microcrystals are simply pure crystalline drug with
sizes on the micron scale. This would allow for much higher loading of microneedles with drug,
although the controlled release properties might be significantly affected. There were two main
approaches to synthesizing the microcrystals: precipitate the crystals out of dissolved solution
and sonicate the ciprofloxacin in water.
The precipitation method involved first dissolving the ciprofloxacin in pH 2 solution of
water and 2.4 N HCl and then the addition of 0.2M NaOH until the ciprofloxacin precipitated out
of solution. This was done for the 30 mg/mL solution for three different pH change rates. One
was 1 mL of 0.2M NaOH every five seconds, the second was 300 pL of NaOH every 10 seconds,
and the last was 500 pl of 0.2M NaOH every 10 seconds.
The sonication in water method involved creating concentrations of Ciprofloxacin in
water and then sonicating each concentration for one minute at 7 Watts.
The microcrystal solution from each synthesis was then characterized using DLS,
dynamic light scattering, on a Brookhaven 90Plus instrument.
vi. Microneedle synthesis and characterization
Microneedle synthesis and characterization carried out as described in Chapter II, Section
b.v.
vii. Microneedle loading
Microneedle loading carried out as described in Chapter II, Section b.iv.
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c. Results and discussion
i. Standard curve
The ciprofloxacin had a peak absorption at around 270 nm and was linear from 1.25-25
pg/mL, which matched literature values of a peak absorption at 271.4 nm and linear from 2-10
pg/mL35 . The standard curve is plotted below in Figure 16. The dilutions from all three
concentrations as well as the dilutions of ciprofloxacin in 0.2M NaOH were all well correlated,
indicating strong confidence in determining the concentration of ciprofloxacin from absorbance
spectrum.
Ciprofloxacin standard curve
3
y = 0.102x + 0.037
2.5 R
2 
= 0.998
C 1.5
--- 5 mg/mL solution
1 
- Linear (5 mg/mL solution)
0.5
0
0 5 10 15 20 25 30
Concentration (ug/mL)
Figure 16: Ciprofloxacin standard curve, checked with multiple dilutions at different pH as well
as solution in 0.2M NaOH. Error bars derived from replicate measurements of different starting
concentrations (10 mg/mL and 30 mg/mL)
ii. Microparticles
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The same properties for the Saquinavir microparticles were determined for the
ciprofloxacin microparticles in order to fully understand the ciprofloxacin microparticles. Table
5 below shows these properties, which are all expected. Only the yield and total mass per 200
pL aliquot are lower than expected. This is most likely due to the fact that the extra step required
to encapsulate the drug in the internal aqueous phase and subsequent encapsulation in the organic
phase could lead to significant loss of both the drug in the internal aqueous phase as well as a
loss in volume of the aqueous phase which does not become encapsulated and is washed away.
Micropartic Yield: Mass per
les Hydrodyn mass of 200 g L
amic PDI Zeta particles lyophilize
Diameter (polydisper potenti receovere d aliquot
(nm) S.E. sty S.E. al (mV1) S.E. d (%1) (mg9)
PLGA +
CIPRO
(5mg/mL)
(0.5% PVA) 1610.6 71.1 0.149 0.060 -17.18 4.03 36.67% 5.33
PLGA +
CIPRO
(10mg/mL)
(0.5% PVA) 1500.8 60.2 0.022 0.017 -22.44 3.38 47.67% 6.93
PLGA +
CIPRO
(30mg/mL)
(0.5% PVA) 1681.3 127 0.036 0.031 -31.48 1.62 27.50% 4
Table 5: Characterization of ciprofloxacin loaded microparticles with different loading levels
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iii. Microparticle loading
Only the two highest concentrations of ciprofloxacin were encapsulated in the
microparticles. The higher concentration encapsulation showed a higher signal after hydrolysis
of the microparticles. There was also a significant loss during encapsulation of ciprofloxacin for
reasons cited earlier. Table 6, below, shows the different predicted loading and actual loading
for three different concentrations of ciprofloxacin used in the internal aqueous phase.
Loading Actual loading ofparticles
Concentration of internal aqueous (Ciprofloxacin:PLGA+ (mass of ciprofloxacin:
phase Ciprofloxacin) mass of particles)
30 mg/mL 0.158 0.00197
10mg/mL 0.0588 0.000513
Table 6: Different predicted and actual loadings for different concentrations of Ciprofloxacin in
the internal aqueous phase
iv. Microcrystals
The size of the microcrystals seemed highly dependent on concentration. There was a
large distribution of sizes ranging from a few hundred nanometers to tens of microns. The
majority of distribution, however, was between 1 and 10 microns. The precipitated method
seemed to cause a more uniform distribution.
The sonicated microcrystals used in the microneedles had a measured concentration of
.0077 mg/sL, which translated to a maximum of 537 pg in each microneedle array. The
precipitated microcrystals had a hypothetical maximum concentration of .03 mg/ pL, which
would translate to a promising 2.1 mg per microneedle array. In actuality, it was slightly lower
due to dilution from the HC1 and NaOH. There was not a significant affect from altering pH or
altering pH change on the size of the microcrystals.
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v. Microneedles
The images below, Figure 17, show the microneedles from two loadings of the
ciprofloxacin microparticles and the two different microcrystal syntheses. The two images of the
ciprofloxacin microparticle loaded microneedles have a difference in coloration due to the
loading of the microparticles. The microneedles loaded with the ciprofloxacin microcrystals,
however, show no difference in coloration due to the acidity of the PAA dissolving the
microcrystals. This phenomenon could have a very interesting effect when introduced into the
more basic plasma or blood solution in the human body, where it would then crystallize
depending on the concentration. Because of the low concentration, it might in fact stay dissolved
and not recrystallize. These are questions that remain to be answered.
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Figure 17: From top left to right: 30 mg/mL Cipro MP MN, 10 mg/mL Cipro MP MN; bottom
left to right: sonicated ciprofloxacin microcrystal MN, precipitated ciprofloxacin microcrystal
MN
vi. Microneedle loading
The microneedles loaded with the ciprofloxacin microparticles demonstrated a signal
corresponding to .41 pg of ciprofloxacin per array for the 30 mg/mL concentration of
ciprofloxacin in the microparticles and 0.177 pg of ciprofloxacin per array for the 10 mg/mL
concentration of ciprofloxacin in the microparticles. Based on the ciprofloxacin loading in
microparticles for these two concentrations, this would indicate 208 pg of microparticles and 345
sg of microparticles in the 30 mg/mL and 10 mg/mL ciprofloxacin microneedle arrays,
respectively. These numbers are a factor of 2 to 3 lower than the calculating loading capacity of
approximately Img for each microneedle array. One factor that could contribute to this is that
much of the microparticles are centrifuged between the microneedles as opposed to into the
microneedles.
The microneedle arrays loaded with the sonicated microcrystals led to a loading of 1.7 sg
of ciprofloxacin per array. The arrays with the precipitated microcrystals led to a loading of 165
pg of ciprofloxacin per array. The sonicated microcrystals loaded microneedles produced a
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loading much lower than expected, but the precipitated microcrystals loaded microneedles
showed promise, although they were still an order of magnitude lower than expected. Based on
the calculated concentrations, a maximum of 175 pg and 2.1 mg of microcrystals for the
precipitated and sonicated microcyrstals should have been expected, respectively. A reason for
this discrepancy could be that because of the varied size distribution for both microcrystals, but
particularly the sonicated microcrystals, the larger crystals could have blocked the other sizes
from centrifuging down into the microneedles. In addition, the smaller sizes of less than 1
micron would not centrifuge down and would be washed away. Finally, much could have been
centrifuged in between the microneedles, which would have been washed away before the PAA
addition, instead of into the microneedles.
Using the analogous insulin analysis, the 165 pg from the precipitated Ciprofloxacin
microcrystals would translate to 1.1 ng/mL. This is well below to approximately 1 pg/mL
needed for a minimum inhibitory concentration. If the entirety of the 1 mg was loaded using the
microcrystals, however, this would lead to 6.67 ng/mL, still too low to cover the highest required
concentration of antibiotics. Some strains of bacteria, however, require .062 pg/mL, meaning the
application of ten arrays would be sufficient to reach this desired concentration.
d. Conclusion
This work had demonstrated the ability to load microneedles with an antibiotic,
Ciprofloxacin, through the use of Ciprofloxacin crystals and through the loading of
Ciprofloxacin in PLGA microparticles. Further investigation is needed to determine whether or
not the loadings are sufficient as is, but regardless, there exists significant room for improvement
in the loading. The biggest area is to capture the approximately 1 mg of loading capacity of the
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microneedles. This will be best achieved through the use of microcrystals with increased
concentration and increased uniformity in size.
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IV. Conclusion
a. Summary
The results from this work are very promising to the eventual goal of using microneedles
to deliver antiretrovirals and antibiotics. First, microparticles were synthesized and proved to be
loading Saquinavir and Ciprofloxacin. Microcrystals were also synthesized for Ciprofloxacin.
Microneedles were synthesized and showed loading of Saquinavir and Ciprofloxacin. It still
remains unclear whether the loadings are sufficient for the intended applications, requiring
further investigation.
b. Future work
Although this work was a good step forward, there is still significant work in order to
demonstrate the efficacy of using microneedles to deliver antiretrovirals and antibiotics. There
exist two main areas to further this investigation. The first area is increasing the loading of the
microneedles. Microcrystals show promise of achieving the entirety of the 1 mg loading limit of
the microneedles. To further this limit, larger needles or potentially a reservoir driven device to
deliver even more drug might be designed. The other main component left to be done is in vivo
experiments to understand the concentrations of the plasma from the microneedle application.
This can be done by applying microneedles loaded with drug and then measuring the
concentration of the drug in the plasma at different time points.
If these measurements prove the presence of the drug in reasonable concentrations, the
next step would be further investigation on the release characteristics of the drug. This would
entail the use of different materials or suspension of the drug in various matrices of
biodegradable materials. The ideal drug concentration in plasma over time would vary
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depending on the drug and its intended use. The drug concentration profile over time would
dictate the desired release of the drug. The third area of further research, after increasing the
loading of the drug and measuring sufficient concentrations in vivo, would be not only to
characterize the release characteristics of the drug, but to develop a system to allow tunable
release. Since microcrystals demonstrate more promise due to higher loading capabilities, new
mechanisms for controlled drug release need to be considered. One such idea would be to
substitute the PAA matrix for various other biodegradable matrices in order to obtain the desired
controlled release, while maintaining other characteristics, including mechanical stability.
Another idea could complement the use of a reservoir to increase drug loading by developing the
reservoir to allow for controlled release. This could include a specific release rate from the
reservoir through the use of a selective membrane and osmotic pressure drive, thus allowing for
tunable controlled release. There exist various methods of controlled release that could all be
implemented in this system.
Achieving a high loading and controlled release microneedle system with demonstrated
sufficient in vivo concentration measurements would be a huge advancement in the field of
microneedle research. The work achieved thus far has laid the foundation for the future work to
improve on the current system.
49
Acknowledgments
This work could not have been possible without the dedicated efforts of a number of
individuals. I would like to thank all of these individuals for their constant support throughout
the entirety of this project. First, I would like to thank Peter DeMuth for his continued guidance
and valued input during this project. Working with him on a regular basis was a pleasure and his
mentorship helped guide me. I would also like to thank the rest of the Irvine lab for their help
and expertise on various parts of this project. Next, I would like to thank Professor Irvine for his
keen advice and generous support for this project as well as for his dedicated instruction in
courses leading up to this project that helped prepare me to accomplish this project. Finally, I
would like to thank all my family and friends for their unwavering support throughout the last
four years.
50
Works cited
[1] Jain, Ashish. Microneedles: A revolution of Transdermal Drug Delivery. Pharmainfo.net.
Posted Friday, May 2, 2008. Accessed April 2 7th 2012.
<http://www.pharmainfo.net/reviews/microneedles-revolution-transdermal-drug-delivery>
[2] Daugherty AL, Mrsny RJ. Emerging technologies that overcome biological barriers for
therapeutic protein delivery. Expert Opinion on Biological Therapy 2003;3(7): 1071-81.
[3] Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults:prevalence and
associations. American Journal of Tropical Medicine and Hygiene 2003;68(3):341e4.
[4] Ranjith Kumar et al., Review on Needle free drug delivery systems. Int. J. Rev. Life. Sci.,
1(2), 2011, 76-82
[5] Gill H. S., Denson D. D., Burris B. A. & Prausnitz M. R. Effect of microneedle design on
pain in human volunteers. Clin JPain 24, 585-594 (2008).
[6] Benjamin, David. Basic Pharmacology. Clinical Pharmacology. Accessed April 27h, 2012.
<http://www.doctorbeniamin.com/pharm/pharm.htm>
[7] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261-1268.
[8] Dezutter-Dambuyant C, Charbonnier AS, Schmitt D. [Epithelial dendritic cells and HIV-1
infection in vivo and in vitro]. PatholBiol (Paris). 1995 Dec;43(10):882-8.
[9] Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B: The globalimpact of HIV/AIDS.
Nature 2001, 410:968-973.
[10] Panel of Clinical Practices for Treatment of HIV Infection, Guidelines for the use
ofantiretroviral agents to treat HIV infection in pediatric patients, Pan. Am. J. PublicHealth
10 (2001) 426-435.
[11] C.A. Shah, Adherence to high activity antiretroviral therapy (HAART) in pediatricpatients
infected with HIV: issues and interventions, Indian J. Pediatr. 74 (2007)55-60.
[12] LookChem. Saquinavir Basic Information. Accessed April 2 8th 2012.
<http://www.lookchem.com/Saquinavir/>
[13] Martin-Facklam M, Burhenne J, Ding R, et al. Dose-dependent increase of saquinavir
bioavailability by the pharmaceutic aid cremophor EL. Br J ClinPharmacol. 2002;53:576-
81.
[14] Gold Standard Inc. Saquinavir. Revised 12-9-2010. Accessed April 29th 2012.
<http://americareoncall.com/vahoo site admin/assets/docs/INVIRASE.53102229.pdf>
[15] Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine,
and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41(11):2428-
2432.
[16] Boffito M., et al. 2005. Boosted saquinavir hard gel formulation exposure in HIV-infected
subjects: ritonavir 100 mg once daily versus twice daily. J. Antimicrob. Chemother. 55:542-
545.
[17] AIDSinfo. Saquinavir mesylate. Last updated March 4,2012. Accessed April 3 0 h 2012.
<http://aidsinfo.nih.gov/drugs/164/saquinavir-mesylate/patient/>
51
[18] Back DJ, Khoo SH, Gibbons SE, et al. The role of therapeutic drug monitoring in treatment
of HIV infection. Br J ClinPharmacol. 2001;51:301-308.
[19] Dickinson L, Boffito M, Khoo SH, et al. Pharmacokinetic analysis to assess forgiveness of
boosted saquinavir regimens for missed or late dosing. J AntimicrobChemother 2008;62:161-
7.
[20] RxList. Selzentry. The internet drug Index. Accessed May 1"', 2012.
<http://www.rxlist.com/selzentry-drug/indications-dosage.htm>
[21] Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK (April
2008). "Assessment of the absorption, metabolism and absolute bioavailability of maraviroc
in healthy male subjects". British Journal of Clinical Pharmacology 65 (Suppl 1): 60-
7. doi:10. 111 1/j.1365-2125.2008.03137.x
[22] DrugBank. Maraviroc. Open Data Drug and Drug Target Database. Accessed May 1't 2012.
<http://www.drugbank.ca/drugs/DB04835>
[23] MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new
class of antiretroviral agents. Clin Infect Dis. 2008;47:236-241
[24] ChinyereOkoli, Marco Siccardi, Sathish Thomas-William, NgoziDufty, Kirstin
Khonyongwa, Jonathan Ainsworth, John Watson, Roseanne Cook, Kate Gandhi, Geraldine
Hickinbottom, Andrew Owen, and Stephen Taylor. Once daily maraviroc 300 mg or 150 mg
in combination with ritonavir-boosted darunavir 800/100 mg. J. Antimicrob. Chemother.
2011 : dkr493vl-dkr493
[25] Ha H.R., Follath F., Bloemhard Y., Krahenbuhl S. Determination of saquinavir in human
plasma by high-performance liquid chromatography. (1997) Journal of Chromatography B:
Biomedical Applications, 694 (2) , pp. 427-433.
[26] Van Heeswijk RP, Hoetelmans RM, Harms R, et al. Simultaneous quantitative
determination ofthe HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and
saquinavir in human plasma by ion-pair high-performance liquid chromatography with
ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;719:159-168
[27] RxList. Invirase. The Internet Drug Index. Accessed May 1', 2012.
<http://www.rxlist.com/invirase-drug.htm>
[28] Sigma-Aldrich. Saquinavir-mesylate. Date accessed May Ist 2012.
<http://www.sigmaaldrich.com/catalog/product/sigma/s8451 ?lang=en&region=US>
[29] Notari, S.,Tommasi, C.,Nicastri, E.,Bellagamba, R.,Tempestilli, M., et al.
( 2009) Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-
UV. IUBMB Life, 61, 470-475.
[30] Sigma-Aldrich. Maraviroc. Date accessed April 2 4 h, 2012.
<http://www.sigmaaldrich.com/catalog/product/sigma/pzOO02?lang=en&region=US>
[31] Gupta J. Felner El. Prausnitz MR. Minimally invasive insulin delivery in subjects with type
1 diabetes using hollow microneedles. Diabetes TechnolTher. 2009; 11:329-337
[32] Borden Institute. Chapter 10: Infections. Accessed April 2 2 nd, 2012.
<http://www.bordeninstitute.army.mil/other pub/ews/Chp10Infections.pdf>
52
[33] FDA. Cipro Tablets. 2004 Bayer Pharmaceuticals Corporation. Accessed April 2 4 th 2012.
<http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPrepar
edness/UCM130802.pdf>
[34] Kumar R, Aneja KR, Roy P, Sharma M, Gupta R, Ram S. Evaluation of minimum
inhibitory concentration of quinolones and third generation cephalosporins to Salmonella
typhi isolates. Indian J Med Sci 2002;56:1-8
[35] Univgraph. Ciprofloxacin. Accessed May ISt, 2012.
<http://www.univgraph.com/bayer/inserts/ciprotab.pdf>
[36] Sigma-Aldrich. Ciprofloxacin. Accessed April 25th
2012.<http://www.sigmaaldrich.com/catalog/product/fluka/I 7850?lang=en&region=US>
[37] Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. NanoCipro encapsulation
in monodisperse large porous PLGA microparticles. J Control Release. 2007;121:100-109.
[38] Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman
JB, Barends DM. 2010. Biowaiver monographs for immediate release solid oral dosage
forms: Ciprofloxacin hydrochloride. JPharm Sci 100(l):22-33
[39] Patel SA, Patel NM, Patel MM. Simultaneous spectrophotometric estimation of
Ciprofloxacin and Ornidazole in tablets. Indian J Pharm Sci 2006;68:665-7
53
